Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (464)	2/24/2005 9:08:23 PM
From: CrazyPete	Read Replies (1) of 946

> That leaves the remaining 10-20% of the dose to do the heavy lifting That seems clear. > the rates of metabolism are not relevant I disagree. I think that would be a serious oversimplification of a complicated pharmacokinetic question. I think that for nearly all drugs, most of the drug ends up never reaching the target tissue, so the disposition of the 80-90% excreted in this case doesn't seem particularly worrying. I think in most cases, you would be lucky if one percent of a chemotherapeutic agent in the general circulation ended up in a tumor. And what happens to that small fraction of the drug is very dependent on relative rates of metabolism in the tumor, versus clearance. Say that 100% of the drug was excreted as the active form. Would that be better? Not clear. The argument is that the conjugated form is delivered more efficiently to the tumor, where it is converted to the active form; so if it is rapidly converted to the active form by other tissues, that could result in delivery of less drug to the tumor. The change in excretion at least tells us that the conjugation made a difference.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next